Online Tool Helps Improve Record-Keeping Compliance, Communication Between Patients and Healthcare Providers. (PRWeb Apr 22, 2008) Read the full story at
Increased popularity further establishes OpenClinica as the most widely used open source software for eClinical Research (PRWeb Apr 22, 2008) Read the full story at
Spurred by growing awareness of the harmful health risks associated with smoking, such as, cancer, heart disease, chronic obstructive pulmonary disease (COPD), and emphysema, to name a few, the world market for smoking cessation aids is forecast to reach $2.6
Americas Watchdog's is conducting a national out reach to surgical patients who may have been given the drug Trasylol during heart surgery or hip replacement surgery. The group is conducting a national investigation to determine if individuals exposed to Trasylol
PanGenex Corporation (Pink Sheets:PGXC) announces that on April 8th, 2008, the Company completed the acquisition of Calgenex Corporation. Calgenex develops and markets proprietary formulations to address specific health conditions. Calgenex has developed a line of nutraceuticals including Calci-CLEAR(TM) to address
Inflexxion® Inc. announced today the launch of a new informational website to support its NAVIPPRO™ pharmaceutical risk management system at www.NAVIPPRO.com. (PRWeb Apr 21, 2008) Read the full story at http://ww1.prweb.com/releases/2008/04/prweb875124.htm
Caraco Pharmaceutical Laboratories has confirmed that the District Court of New Jersey has granted the company's motion for summary judgment that the claims of US patent that Ortho-McNeil Pharmaceutical asserted against Caraco are invalid.
UCB has presented data from a multi-center trial that supported the potential for adjunctive use of intravenous lacosamide 200-600mg/day using infusion durations as fast as 10 minutes, for short term replacement of oral lacosamide in adult patients with partial onset
I-many, a provider of contract management software and services for the enterprise, has announced that a major pharmaceutical company has extended its subscription agreement with I-many for the use of I-many Cars NG, I-many Medicaid Rebates, and I-many Government Pricing.
Obetech, a tenant in the Virginia Biosciences Development Center incubation program at the Virginia Biotechnology Research Park, has announced a joint venture with Scandinavian Clinical Nutrition, a Swedish organization focused on development of dietary supplements.
Oncologix Tech has signed a non-binding memorandum of understanding with Institut fur Unwelttechnologien, a German company, for the continued development and commercialization of its Oncosphere product.
GlaxoSmithKline has announced final results from a prospective study which demonstrated that lapatinib decreases tumourigenic stem cells in primary breast cancers of women receiving neoadjuvant treatment.
Nereus Pharmaceuticals has started enrollment in a Phase Ib study evaluating the proteasome inhibitor NPI-0052 in combination with vorinostat in patients with selected solid tumor malignancies.
Bennu Pharmaceuticals, a clinical development subsidiary of Raptor Pharmaceuticals, has started the first clinical-stage program after dosing the first cohort in a Phase IIa study of oral 4-methylpyrazole in subjects with ALDH2 deficiency, or ethanol intolerance, as the initial development
